The board of SoftOx Solutions AS has entered into a loan agreement with Almhaug
Bolig AS, where the main shareholder is one of the shareholders. Almhaug Bolig
AS will provide the company with a short-term loan of NOK 15 million.

"In the last year, the company has experienced some delays both in connection
with regulatory processes with the authorities and in the implementation of
certain clinical studies. To compensate for the liquidity burden caused by these
delays, the company's main shareholder has given the company a loan of NOK 15
million. Additional supply of liquidity may be considered if desired. The
company is grateful that the company's main shareholder shows his support for
the company I this situation. It is important for the company to have owners who
are dynamic and support the company financially in such situations", says CEO
Geir Almaas of SoftOx Solutions.

 "We work with several exciting processes. Among other things, we recently
received approval from the Danish Medicines Agency to start SIS (SoftOx
Inhalation solution) studies in humans. For us, this is a very exciting race,
which we have high expectations for", Almås continues.

The loan has a maturity of 12 months and is not interest-bearing. The loan will
in principle be repaid in cash, but until the maturity of the loan, Almhaug
Bolig AS will have the right to convert the loan into equity in the company by
issuing new shares at a price equal to the volume- weighted average share price
in the last five days before entering into the agreement, minus five percent,
NOK 38,551 per share. The board is of the opinion that the discount is
commercially justified as the loan is interest-free. If the company carries out
a share issue before the loan matures or is converted into shares, Almhaug Bolig
AS will have the right to convert the loan into shares at the same price per
share as the subscription price in such an issue.

New shares that may be issued in connection with the conversion right will be
approved by the company's board in accordance with the authorization given by
the annual general meeting on 13 April 2021. The board has assessed the loan
agreement and the right of conversion in relation to the rules on equal
treatment and is of the opinion that there is a valid reason for differential
treatment.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine M. Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com